Clinical Trial Update: Deucravacitinib in PG [EARLY_Phase 1]

View source ↗

Summary

The EARLY Phase 1 trial of deucravacitinib for pyoderma gangrenosum has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• Deucravacitinib (deucravacitinib)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Pyoderma Gangrenosum | EARLY_Phase 1 | Status: WITHDRAWN